Literature DB >> 26870273

Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2.

Yonghua Shen1, Min Chen1, Shuling Huang1, Xiaoping Zou1.   

Abstract

The Warburg effect is important in tumor growth. The human M2 isoform of pyruvate kinase (PKM2) is a key enzyme that regulates aerobic glycolysis in tumor cells. Recent studies have demonstrated that PKM2 is a potential target for cancer therapy. The present study investigated the effects of pantoprazole (PPZ) treatment and PKM2 transfection on human gastric adenocarcinoma SGC-7901 cells in vitro. The present study revealed that PPZ inhibited the proliferation of tumor cells, induced apoptosis and downregulated the expression of PKM2, which contributes to the current understanding of the functional association between PPZ and PKM2. In summary, PPZ may suppress tumor growth as a PKM2 protein inhibitor.

Entities:  

Keywords:  apoptosis; gastric cancer; proton pump inhibitors; pyruvate kinase M2; tumor metabolism

Year:  2015        PMID: 26870273      PMCID: PMC4727057          DOI: 10.3892/ol.2015.3912

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.

Authors:  Mayumi Tamada; Makoto Suematsu; Hideyuki Saya
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

3.  The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate.

Authors:  M S Jurica; A Mesecar; P J Heath; W Shi; T Nowak; B L Stoddard
Journal:  Structure       Date:  1998-02-15       Impact factor: 5.006

4.  Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.

Authors:  Qian Sun; Xinxin Chen; Jianhui Ma; Haiyong Peng; Fang Wang; Xiaojun Zha; Yanan Wang; Yanling Jing; Hongwang Yang; Rongrong Chen; Long Chang; Yu Zhang; June Goto; Hiroaki Onda; Tong Chen; Ming-Rong Wang; Youyong Lu; Han You; David Kwiatkowski; Hongbing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

5.  Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation.

Authors:  Gilles A Spoden; Sybille Mazurek; Dieter Morandell; Nicole Bacher; Michael J Ausserlechner; Pidder Jansen-Dürr; Erich Eigenbrodt; Werner Zwerschke
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

6.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

7.  A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway.

Authors:  Mi-Sun Won; Namhui Im; Soohyun Park; Shanthaveerappa K Boovanahalli; Yinglan Jin; Xuejun Jin; Kyung-Sook Chung; Moorim Kang; Kiho Lee; Song-Kyu Park; Hwan Mook Kim; Byoung Mog Kwon; Jung Joon Lee; Kyeong Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-05-09       Impact factor: 3.575

Review 8.  Targeting glucose metabolism for cancer therapy.

Authors:  Robert B Hamanaka; Navdeep S Chandel
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

9.  Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression.

Authors:  Michael S Goldberg; Phillip A Sharp
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

10.  MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells.

Authors:  Michio Kosugi; Rehan Ahmad; Maroof Alam; Yasumitsu Uchida; Donald Kufe
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

View more
  8 in total

1.  Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.

Authors:  Sahar K Hegazy; Sahar M El-Haggar; Suzan A Alhassanin; Eman I El-Berri
Journal:  Med Oncol       Date:  2021-01-04       Impact factor: 3.064

2.  Cancer: fundamentals behind pH targeting and the double-edged approach.

Authors:  Tomas Koltai
Journal:  Onco Targets Ther       Date:  2016-10-17       Impact factor: 4.147

Review 3.  A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.

Authors:  Li-Yuan Yu; Lu-Ning Sun; Xue-Hui Zhang; Yue-Qi Li; Lei Yu; Zi-Qing-Yun Yuan; Ling Meng; Hong-Wen Zhang; Yong-Qing Wang
Journal:  Adv Ther       Date:  2017-04-20       Impact factor: 3.845

4.  MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer.

Authors:  Man Guo; Xinying Zhao; Xiaolei Yuan; Jing Jiang; Peiling Li
Journal:  Oncotarget       Date:  2017-04-25

5.  Expression and Transcriptional Regulation of Human ATP6V1A Gene in Gastric Cancers.

Authors:  Pin Wang; Lei Wang; Jie Sha; Guochun Lou; Nannan Lu; Bo Hang; Jian-Hua Mao; Xiaoping Zou
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

Review 6.  Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.

Authors:  Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Claudiu T Supuran; Stefano Fais
Journal:  Metabolites       Date:  2017-12-23

7.  Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection.

Authors:  Abulizi Abudula; Nuermanguli Rouzi; Lixiu Xu; Yun Yang; Axiangu Hasimu
Journal:  Bosn J Basic Med Sci       Date:  2020-02-05       Impact factor: 3.363

Review 8.  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.

Authors:  Bhagyashri Rathod; Shivam Chak; Sagarkumar Patel; Amit Shard
Journal:  RSC Med Chem       Date:  2021-05-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.